Metabolic Pharmaceuticals Limited ASX: MBP - Metabolic Completes Options Study for Obesity Drug: AOD9604 - Dr Roland Scollay, CEO
Sydney, Dec 19, 2006 (ABN Newswire) - Metabolic Pharmaceuticals Limited (ASX: MBP) - Metabolic Completes Options Study for Obesity Drug: AOD9604 - Dr Roland Scollay, CEO; Boardroomradio is pleased to announce that Metabolic Pharmaceuticals Limited (ASX: MBP) has published an audio file. The following presentation "Metabolic Completes Options Study for Obesity Drug: AOD9604" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Develops innovative therapies which have application to large or unmet markets worldwide, including obesity, pain and diabetes.
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
